BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 27013581)

  • 1. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A microchip filter device incorporating slit arrays and 3-D flow for detection of circulating tumor cells using CAV1-EpCAM conjugated microbeads.
    Kim YJ; Koo GB; Lee JY; Moon HS; Kim DG; Lee DG; Lee JY; Oh JH; Park JM; Kim MS; Woo HG; Kim SI; Kang P; Choi W; Sim TS; Park WY; Lee JG; Kim YS
    Biomaterials; 2014 Aug; 35(26):7501-10. PubMed ID: 24917030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
    Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
    Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research.
    Grover PK; Cummins AG; Price TJ; Roberts-Thomson IC; Hardingham JE
    Ann Oncol; 2014 Aug; 25(8):1506-16. PubMed ID: 24651410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM
    Lampignano R; Yang L; Neumann MHD; Franken A; Fehm T; Niederacher D; Neubauer H
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients.
    Perelmuter VM; Grigoryeva ES; Savelieva OE; Alifanov VV; Andruhova ES; Zavyalova MV; Bragina OD; Garbukov EY; Menyailo ME; Khozyainova AA; Denisov EV; Cherdyntseva NV; Tashireva LA
    Sci Rep; 2024 May; 14(1):12245. PubMed ID: 38806508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved detection by ensemble-decision aliquot ranking of circulating tumor cells with low numbers of a targeted surface antigen.
    Johnson ES; Anand RK; Chiu DT
    Anal Chem; 2015 Sep; 87(18):9389-95. PubMed ID: 26302174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
    Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
    Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells.
    Eslami-S Z; Cortés-Hernández LE; Alix-Panabières C
    Cells; 2020 Aug; 9(8):. PubMed ID: 32764280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
    Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
    Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.
    Driemel C; Kremling H; Schumacher S; Will D; Wolters J; Lindenlauf N; Mack B; Baldus SA; Hoya V; Pietsch JM; Panagiotidou P; Raba K; Vay C; Vallböhmer D; Harréus U; Knoefel WT; Stoecklein NH; Gires O
    Oncogene; 2014 Oct; 33(41):4904-15. PubMed ID: 24141784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
    Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
    Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.